• Amarin, Apotex Settle Vascepa Dispute; Analyst Stays Sidelined

    Amarin, Apotex Settle Vascepa Dispute; Analyst Stays SidelinedAmarin (AMRN) has announced a settlement agreement with Apotex Inc. that resolves a patent litigation over Apotex’s abbreviated new drug application (ANDA) seeking US approval of a generic form of Vascepa capsules. Shares in Amarin rose 5% in Tuesday’s after-market trading.Amarin’s lead product Vascepa was initially launched in the US in 2013 as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. A new, cardiovascular risk indication for the fish-oil derivative was approved by the FDA in December 2019 based on the results of the landmark Reduce-It trial.The company is currently appealing to the U.S. Court of Appeals a March 2020 patent invalidity ruling in favor of generic companies, Hikma Pharmaceuticals USA Inc. and Dr. Reddy’s Laboratories, Inc. Because Apotex is not a party to that litigation, it is not directly subject to related rulings.As part of the new settlement agreement, Apotex can not sell a generic Vascepa in the US until August 9, 2029 (the same date as Amarin’s 2018 settlement agreement with Teva (TEVA)) or earlier under certain customary circumstances.  These circumstances include if Amarin is not successful in its pending appeal of the March 2020 Nevada district court decision.The agreement also substantially resolves future litigation with Apotex that relating to the December 2019 cardiovascular risk reduction indication of Vascepa, says Amarin.“This settlement involves no financial payment from Amarin to Apotex and allows Amarin to avoid incremental litigation expense and distraction associated with Apotex’s participation in patent litigation related to the MARINE and REDUCE-IT indications,” said John F. Thero, Amarin CEO.Year-to-date shares in Amarin have plunged 68%, but analysts retain a cautiously optimistic Moderate Buy outlook on the stock. This breaks down into 7 recent buy ratings vs 5 hold ratings. Meanwhile the average analyst price target of $18 translates into 155% upside potential. (See Amarin stock analysis on TipRanks)Stifel Nicolaus analyst Derek Archila reiterated his Amarin Hold rating following the settlement announcement. “While this is a slight positive, we don’t see this a major stock moving catalyst” he wrote, adding that he expects AMRN shares to remain range bound until it gets closer to the critical appeal hearing later this year.Related News: Too Much Uncertainty Keeps This 5-Star Analyst Watching Amarin Stock From the Sidelines Jazz Pharma Scores Surprise Early Approval For Lung Cancer Treatment Merck’s Gardasil Receives FDA Nod For Expanded Cancer Indications More recent articles from Smarter Analyst: * Fulgent Pops 18% In After-Market On FDA Nod For Covid-19 Home Test * Groupon Rises After-Hours Despite Revenue Plunging 35% Y/Y * Google and Carrefour Roll Out Voice-Based Shopping Service In France * Facebook Unveils Tighter Political Ad Measures Ahead of US Elections

    from Yahoo Finance https://ift.tt/3ebRAAt

  • Fund managers have been buying these ASX shares

    ASX buy

    I like to keep an eye on substantial shareholder notices. This is because these notices give you an idea of which shares large investors, asset managers, and investment funds are buying or selling.

    Two notices that have caught my eye today are summarised below. Here’s what these fund managers have been buying:

    Computershare Limited (ASX: CPU)

    A notice of change of interests of substantial holder shows that AustralianSuper has taken advantage of Computershare’s share price weakness to increase its stake. According to the notice, the super fund has picked up approximately 8 million of this share registry company’s shares over the last four months. This has lifted its holding to a total of ~41.1 million shares, which represents a 7.59% stake in the company.

    The Computershare share price is down 27% from its 52-week high. Judging by its purchases, this has left its shares trading at a level that AustralianSuper thinks is attractive. One broker that would agree with this is Morgans. Last month the broker put an add rating and $13.90 price target on the company’s shares.

    Medibank Private Ltd (ASX: MPL)

    A notice of initial substantial holder reveals that Perpetual Limited (ASX: PPT) has been building a position in this private health insurer over the last few months. Perpetual started buying in February when Medibank’s shares were trading at $3.06. It then continued to purchase shares in March when they fell to ~$2.60 and has consistently added to its holding since then. Its last recorded purchase came on 11 June for $3.01. In total Perpetual now owns 140,759,820 shares, which represents a 5.11% stake in the company.

    As with AustralianSuper and Computershare, it appears as though the fund manager sees value in Medibank’s shares after they fell 18% from their high. Affordability issues have been weighing heavily on the company over the last 12 months, but AustralianSuper doesn’t appear concerned.

    And here are more quality shares which I think fund managers could be buying…

    5 ASX stocks under $5

    One trick to potentially generating life-changing wealth from the stock market is to buy early-stage growth companies when their share prices still look dirt cheap.

    Motley Fool’s resident tech stock expert Dr. Anirban Mahanti has identified 5 stocks he thinks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Fund managers have been buying these ASX shares appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3dbzttb

  • 5 ASX shares that would’ve made you a fortune in 5 years

    Wealthy man with money raining down, cheap stocks

    Finding ASX shares that can make you a fortune in just 5 years is every investor’s dream. Investing in that one knockout winner can make a life-changing impact on your portfolio and your personal wealth. Of course, the ASX boards are littered with the broken dreams of those investors who’ve made the wrong bets. We can’t all find the next Amazon.com.

    But we can take a look at some past ASX winners that made their investors very rich over the past 5 years.

    CSL Limited (ASX: CSL)

    CSL is one of those rare shares that has made an absolute motza for its investors over the past 5 years, despite its size and blue chip status. Five years ago, CSL shares were trading at $87.40 each. Fast forward to today and CSL shares will set you back $286.22 (at the time of writing). That’s a 227% gain in 5 years.

    Xero Limited (ASX: XRO)

    Xero has been another ASX fortune maker over the past 5 years. This cloud-based accounting software provider was a slow burner in its infancy but has really stepped on the gas over the past few years, as its scalable business model works its magic. Five years ago, Xero shares were asking just $17.06. Today, those same shares will set you back $88.39. That’s more than 400% in gains that investors have enjoyed since 2015.

    Northern Star Resources Ltd (ASX: NST)

    It’s not often that ASX gold miners are cited as favoured money makers, but ask any Northern Star shareholder for their opinion on the matter. This mid-cap miner’s shares have spent the past 5 years rocketing from $2.28 in 2015 to $13.20 today. If you go back another 5 years to 2010, Northern Star was just 6 cents per share. Who said that gold doesn’t glitter! Any lucky shareholder that acquired Northern Star ownership in 2015 would be looking at nearly a 480% gain today. And for anyone who got in back in 2010? Hello 22,000%.

    Afterpay Ltd (ASX: APT)

    Afterpay’s phenomenal success would probably be familiar to every ASX investor by now. After all, this buy now, pay later pioneer is a share that is up more than 35% in just the last month alone. But what of those long-term investors in Afterpay? Well, back in 2015, you could have picked up Afterpay shares for just $2.95. Fast forward to today and Afterpay is making yet more record highs, going for $57.34 at the time of writing. That’s a 1,844% return since 2015. Talk about a fortune maker!

    Fortescue Metals Group Limited (ASX: FMG)

    Much like CSL, this ASX blue chip iron miner doesn’t immediately come to mind as a ‘multi-bagger‘ share. Yet this company’s numbers tell a different story. Back in 2015, you could have picked up some Fortescue shares for just $2.16. Today, those same shares will set you back $14.61 – netting any lucky buyer in 2015 a 576% increase in their fortune. Not bad for a red dirt digger.

    For some potential multi-baggers of tomorrow, make sure you check out the shares named below.

    3 “Double Down” stocks to ride the bull market higher

    Motley Fool resident tech stock expert Dr. Anirban Mahanti has identified three stocks he thinks can ride the bull market even higher, potentially supercharging your wealth in 2020 and beyond.

    Doc Mahanti likes them so much he has issued “double down” buy alerts on all three stocks to members of his Motley Fool Extreme Opportunities stock picking service.

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and Xero. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 5 ASX shares that would’ve made you a fortune in 5 years appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/37FWljh

Sorry, but nothing was found. Please try a search with different keywords.